Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
Public ClinicalTrials.gov record NCT03719664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection
Study identification
- NCT ID
- NCT03719664
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Frontier Biotechnologies Inc.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Albuvirtide Drug
- 3BNC117 Drug
- Baseline ART Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 16, 2018
- Primary completion
- Nov 30, 2022
- Completion
- Nov 30, 2022
- Last update posted
- Sep 28, 2021
2018 – 2022
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ABT-3BNC117_201 Investigational Site | Palm Springs | California | 92262 | Recruiting |
| ABT-3BNC117_201 Investigational Site | San Francisco | California | 94115 | Recruiting |
| ABT-3BNC117_201 Investigational Site | Ft. Pierce | Florida | 34982 | Recruiting |
| ABT-3BNC117_201 Investigational Site | Hialeah | Florida | 33016 | Recruiting |
| ABT-3BNC117_201 Investigational Site | Orlando | Florida | 32803 | Recruiting |
| ABT-3BNC117_201 Investigational Site | Atlanta | Georgia | 30312 | Recruiting |
| ABT-3BNC117_201 Investigational Site | New York | New York | 10029 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03719664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03719664 live on ClinicalTrials.gov.